Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared <i>KRAS</i> and <i>TP53</i> mutations expressed by solid tumors in first-in-human phase 1 study.

Maria Pia Morelli, Scott Kopetz, Matthew R. Collinson-Pautz et al.|Journal of Clinical Oncology|2023

Cited by 12